Cost and supply considerations for antibody therapeutics
Monoclonal antibodies (mAbs) and mAb-derived biologics have achieved substantial success across various therapeutic areas over recent decades. Their widespread adoption, however, remains constrained due to high prices and challenges in supply. Here, we examine the general price and cost structure of...
Saved in:
Main Authors: | Chun Chen, Zoe Garcia, David Chen, Hong Liu, Piper Trelstad |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2025.2451789 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras
by: Brian Kelley
Published: (2024-12-01) -
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge
by: M. Biddle, et al.
Published: (2024-12-01) -
Biparatopic antibodies: therapeutic applications and prospects
by: David L. Niquille, et al.
Published: (2024-12-01) -
Editorial: The immune response to therapeutic antibodies
by: Michael G. Tovey, et al.
Published: (2025-02-01) -
Opportunity Cost Classification of Goods and Markets
by: Davor Mance, et al.
Published: (2015-03-01)